Abstract:Jian-Jun Xi, 1, &ast Yu Cao, 1, &ast Ruo-Yu He, 1 Jian-Kang Zhang, 2 Yan-Mei Zhao, 1 Qiao Tong, 1 Jian-Feng Bao, 1 Yi-Chen Dong, 3 Rang-Xiao Zhuang, 1 Jin-Song Huang, 1 Yongping Chen, 4 Shou-Rong Liu 1 1 Department of Pharmacy, Hangzhou Xixi Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, People's Republic of China; 2 School of Medicine, Zhejiang University City College, Hangzhou, People's Republic of China; 3 Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, People's Republic of China; 4 Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Hepatology Institute of Wenzhou Medical University, Wenzhou Key Laboratory of Hepatology, Wenzou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yongping Chen, Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Hepatology, Hepatology Institute of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325025, People's Republic of China, Email Shou-Rong Liu, Department of Infectious Diseases, Hangzhou Xixi Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310023, People's Republic of China, Email Objective: Silibinin, a natural product extracted from the seeds of the Silybum marianum , is versatile with various pharmacological effects. However, its clinical application was strongly hampered by its low bioavailability and poor water solubility. Herein, a series of glycosylated silibinin derivatives were identified as novel anti-tumor agents. Materials and Methods: The cell viability was evaluated by CCK8 assay. Furthermore, cell apoptosis and cell cycle progression were tested by flow cytometry. In addition, the pharmacokinetic assessment of compound 15 and silibinin through intravenous administration (i.v., 2 mg/kg) to ICR mice were performed. Results: The synthesized compounds showed better water solubilities than silibinin. Among them, compound 15 exhibited inhibitory activity against DU145 cells with IC 50 value of 1.37 ± 0.140 μ M. Moreover, it arrested cell cycle at G2/M phase and induced apoptosis in DU145 cells. Additionally, compound 15 also displayed longer half-life (T 1/2 = 128.3 min) in liver microsomes than that of silibinin (T 1/2 = 82.5 min) and appropriate pharmacokinetic parameters in mice. Conclusion: Overall, glycosylation of silibinin would be a valid strategy for the development of silibinin derivatives as anti-tumor agents. Graphical Keywords: glycosylation, silibinin derivatives, solubility, anti-proliferative activity Graphical Silymarin is a representative extract derived from the seeds of milk thistle ( Silybum marianum ), which consists of several flavonoid lignin-like compounds (silibinin, isosilybin and silychristin) (Figure 1). 1–4 Silibinin, the most abundant active ingredient of silymarin, exhibits a variety of characteristics in terms of therapeutic activities, including antioxidant, free radicals scavenging, maintaining the stability of cell membrane, promoting hepatocyte proliferation and reducing blood lipids. 5,6 Several animal studies in vivo have confirmed that silibinin possesses a significant inhibitory effect on different types of tumors including liver, colon, prostate, bladder and tongue through the suppression of receptor tyrosine kinase (RTK) represented by epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-1R) and the activation of downstream signaling molecules. 7–9 Additionally, enhanced efficacy of chemotherapy drugs can be achieved through combination with silibinin, avoiding the appearance of multidrug resistance (MDR). 10 Figure 1 Chemical structures of respective components of silymarin. Despite a widespread use of silibinin for the treatment of various liver ailments for more than 3 decades, the pharmacological properties of silibinin are considerably hampered by its poor water solubility. 11–14 Numerous approaches have been developed to overcome the low bioavailability of silibinin by means of the structural modification, delivery strategies and so on. 15,16 On the one hand, silibinin derivatives can be obtained by the etherification, oxidation and esterification of hydroxyl groups of silibinin, formation of salts or the co -Abstract Truncated-

Biotransformation on the Flavonolignan Constituents of Silybi Fructus by an Intestinal Bacterial Strain Eubacterium Limosum ZL-II.

Synthesis and Biological Evaluation of Deferiprone-Resveratrol Hybrids As Antioxidants, Aβ1–42 Aggregation Inhibitors and Metal-Chelating Agents for Alzheimer's Disease

Inhibition of Lysozyme Amyloid Fibrillation by Silybin Diastereoisomers: The Effects of Stereochemistry

Inhibition of Aβ Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry

Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.

Silymarin Glyceryl Monooleate/Poloxamer 407 Liquid Crystalline Matrices: Physical Characterization and Enhanced Oral Bioavailability

Silybin-derived Flavonolignans and Their Structure-Activity Relationships: Research Advances.

Metal Coordination Protocol for the Synthesis Of-2,3-dehydrosilybin and 19-O-demethyl-2,3-dehydrosilybin from Silybin and Their Antitumor Activities

Biotransformation of Flavonoids Improves Antimicrobial and Anti-Breast Cancer Activities in Vitro

Synthesis and Antioxidant Properties of Novel Silybin Analogues

[Identification of flavonoids 3-hydroxylase from [Silybum marianum (L.) Gaertn] and its application in enhanced production of taxifolin]

Design, Synthesis and Biological Evaluation of Glycosylated Derivatives of Silibinin as Potential Anti-Tumor Agents

Silymarin’s Inhibition and Treatment Effects for Alzheimer’s Disease

Synthesis and Antioxidant Evaluation of Novel Silybin Analogues

Silybin A from reprograms lipid metabolism to induce a cell fate-dependent class switch from triglycerides to phospholipids

In vitro assessment of the effects of silybin on CYP2B6-mediated metabolism

Silibinin Schiff Base Derivatives Counteract CCl4-Induced Acute Liver Injury by Enhancing Anti-Inflammatory and Antiapoptotic Bioactivities

Preparation of Silybin 23-Esters and Evaluation of Their Inhibitory Ability Against LPO and DNA Protective Properties

Preparation of C-23 Esterified Silybin Derivatives and Evaluation of Their Lipid Peroxidation Inhibitory and DNA Protective Properties

Design, Synthesis, and Examination of Neuron Protective Properties of Alkenylated and Amidated Dehydro-Silybin Derivatives

Unlocking the possibilities of therapeutic potential of silymarin and silibinin against neurodegenerative Diseases-A mechanistic overview